Tahata et al. also reported that HCC occurrence in patients with SVR did not differ by therapy in propensity score-matched analysis (cumulative rates of HCC occurrence at 1 year and 2 years: 0.5% and 1.9% in the IFN-based group vs 1.1% and 3.0% in the IFN-free group, P = 0.489; adjusted HR (95% CI) vs IFN-based: 1.134 (0.367–3.498), P = 0.827)38. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.